Skip to main content
. 2018 May 8;18:67. doi: 10.1186/s12890-018-0640-6

Table 1.

Participants clinico-demographic data

Variable All n = 284 HIV+/ PTB+ n = 145 HIV+/ PTB n = 139 p - value
Age median(IQR) 38 (32–46) 38 (32–44) 38 (32–47) 0.534
Female 142 (50) 72 (49.6) 70(50.4) 0.893
On cART 140(49.3) 62 (47.3) 78(56.1) 0.138
Duration of cART (months) Median(IQR) 21 (1–58) 10 (1–48) 32 (9–58) 0.076
Alive at Week-8 Follow-up 191(70.7) 90(62.1) 101(72.7) 0.057
Duration of Hospital Stay (Days) Median(IQR) 5(3–8) 4(3–7) 5(4–10) < 0.001
CD4 T-lymphocytes count (cells/μL) median(IQR) 54(18–144) 41 (14–110) 86(25–220) < 0.001
BMI Median(IQR) 19.2(17.0–21.5) 19.1(16.6–20.8) 19.2(17.3–21.8) 0.222
BMI ≤18.5 95(33.4) 48(33.1) 47(33.8) 0.901
On efavirenz based regimen 109(38.3) 48(33.1) 61 (43.9) 0.061
Haemoglobin g/dl mean(SD) 9.2(2.8) 8.6(2.4) 9.6(3.0) 0.030

Key: n = number of participants in category, IQR interquartile range, SD standard deviation, BMI Body Mass Index, cART combination Antiretroviral therapy, All values are stated as n(%) unless indicated otherwise. p-values of ≤ 0.05 were considered statistically significant